Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status

被引：1
|
作者：
Garrison, L. P.
Lalla, D.
Brammer, M. G.
Wang, B.
Babigumira, J.
Perez, E. A.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Mayo Clin, Jacksonville, FL 32224 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.6133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6133
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status
    Garrison, Louis P., Jr.
    Lalla, Deepa
    Brammer, Melissa
    Babigumira, Joseph B.
    Wang, Bruce
    Perez, Edith A.
    CANCER, 2013, 119 (17) : 3113 - 3122
  • [2] Prevalence of "HER2 ultra-low" among patients with advanced breast cancer with historical IHC0 status
    Mehta, Sandhya
    Iyengar, Anushree
    Barman, Hannah
    Rangarajan, Nivedita
    Woo, Michele Sue-Ann
    Sredni, Simone T.
    Di Donato, Rosemarie
    Simsek, Safak
    Downs, Erinn P.
    Nassar, Aziza
    Wilson, Darren M.
    Krieser, Katherine
    Patzke, Elise Bieri
    Kyek, Natalie
    Hipp, Jason
    Wagner, Tyler
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
    Farah, Eliya
    Carbonell, Chantelle
    Boyne, Devon J.
    Brenner, Darren R.
    Henning, Jan-Willem
    Moldaver, Daniel
    Shokar, Simran
    Cheung, Winson Y.
    CANCERS, 2024, 16 (03)
  • [4] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [5] Lower response to T-DM1 in metastatic breast cancer patients with HER2 IHC score of 2 and FISH positive compared with IHC score of 3
    Yazaki, S.
    Hashimoto, J.
    Ogita, S.
    Nakano, E.
    Yamauchi, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Accurate assessment of HER2 status in "triple-negative" breast cancer requires both IHC and FISH testing
    Ren, Q.
    Alexander, M.
    Samdani, R.
    Singh, B.
    CANCER RESEARCH, 2013, 73
  • [7] Accurate assessment of HER2 status in 'triple-negative' breast cancer requires both IHC and FISH testing
    Ren, Q.
    Samdani, R.
    Singh, B.
    HISTOPATHOLOGY, 2012, 61 : 29 - 29
  • [8] Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
    Hajjar, Ali
    Ergun, Mehmet A.
    Alagoz, Oguzhan
    Rampurwala, Murtuza
    PLOS ONE, 2019, 14 (06):
  • [9] POTENTIAL COST-EFFECTIVENESS OF NERATINIB FOLLOWING TRASTUZUMAB THERAPY FOR TREATMENT OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
    Schwartz, N. R.
    Steuten, L.
    Babigumira, J. B.
    Roth, J. A.
    VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [10] PILHLE-001: neoadjuvant pyrotinib combined with chemotherapy in HR-positive, HER2-low (IHC 2+/FISH-negative) early breast cancer
    Gong, Chang
    Xia, Yuan
    Zhu, Yingying
    Yang, Yaping
    Yang, Wenqian
    Chow, Louis W. C.
    Ling, Li
    Zeng, Yunjie
    Zhong, Jiajie
    Cheng, Ziliang
    Shen, Jun
    Lin, Qun
    Zeng, Yinduo
    Liu, Qiang
    Song, Erwei
    CANCER RESEARCH, 2024, 84 (09)
12345